

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 **SSY Group Limited**

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT COOPERATION AGREEMENT

This voluntary announcement is made by SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”).

The board of directors (the “Board”) of the Company is pleased to announce that Shijiazhuang No. 4 Pharmaceutical Co., Ltd. (“Shijiazhuang No. 4 Pharma”), a wholly-owned subsidiary of the Group, recently entered into a cooperation agreement (the “Cooperation Agreement”) with Professor Jean-Marie Lehn (“Professor Lehn”), the winner of the Nobel Prize in Chemistry, in relation to the establishment of the Nobel Prize Scientific Workstation (the “Workstation”).

Professor Lehn is a worldclass French chemist and also one of the winners of the Nobel Prize in Chemistry in 1987. He mainly researches in supramolecular chemistry and has deep knowledge in the areas of bio-organic chemistry and biology. In particular, he is among the world leaders in the development of drugs for cardiovascular and oncological diseases.

Under the Cooperation Agreement, Shijiazhuang No. 4 Pharma engaged Professor Lehn as the chief academic adviser to establish the Nobel Prize Scientific Workstation and provide services including scientific research and talent cultivation for Shijiazhuang No. 4 Pharma. The Workstation will be relied on Professor Lehn’s team for offering guidance to Shijiazhuang No. 4 Pharma conforming to international standards on screening, development and clinical research of new drugs, accelerating the formation of a talent cultivation mechanism with international exposure, promoting the production progress of technological achievements and accelerating the achievement of transformation for Shijiazhuang No. 4 Pharma from “follower” to “leader” in the field of the development of new drugs.

This Cooperation Agreement and the transactions contemplated thereunder do not constitute a notifiable transaction for the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) nor a connected transaction under Chapter 14A of the Listing Rules.

This announcement is a voluntary announcement made by the Company to keep its shareholders and potential investors informed on the latest business developments of the Group. In the event that any further specific agreement is entered into by the parties of the Cooperation Agreement, the Company will comply with the relevant requirements of the Listing Rules and make a further announcement as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board

Chow Hing Yeung

Company Secretary

Hong Kong, 18 October 2017

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.